A Multicentered Prospective Cohort Study of Chinese IBD Patients

Conditions:   Ulcerative Colitis;   Crohn Disease Interventions:   Drug: Infliximab;   Drug: Vedolizumab;   Drug: Ustekinumab;   Drug: conventional treatment (glucocoticoid, immunosupressive drugs and/or mesalazine) Sponsor:   Peking Union Medical College Hospital Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials